Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA.
Bone. 2011 Jan;48(1):121-8. doi: 10.1016/j.bone.2010.06.029. Epub 2010 Jul 13.
Multiple myeloma is a hematological malignancy that is associated with the development of a destructive osteolytic bone disease, which is a major cause of morbidity for patients with myeloma. Interactions between myeloma cells and cells of the bone marrow microenvironment promote both tumor growth and survival and bone destruction, and the osteolytic bone disease is now recognized as a contributing component to tumor progression. Since myeloma bone disease is associated with both an increase in osteoclastic bone resorption and a suppression of osteoblastic bone formation, research to date has largely focused upon the role of the osteoclast and osteoblast. However, it is now clear that other cell types within the bone marrow, including cells of the immune system, mesenchymal stem cells and bone marrow stromal cells, can contribute to the development of myeloma bone disease. This review discusses the cellular mechanisms and potential therapeutic targets that have been implicated in myeloma bone disease.
多发性骨髓瘤是一种血液系统恶性肿瘤,与破坏性溶骨性骨病的发展有关,这是骨髓瘤患者发病和致残的主要原因。骨髓瘤细胞与骨髓微环境细胞之间的相互作用促进了肿瘤的生长和存活以及骨破坏,目前已将溶骨性骨病视为肿瘤进展的一个促成因素。由于骨髓瘤性骨病与破骨细胞的骨吸收增加和成骨细胞的骨形成抑制均有关,迄今为止的研究主要集中在破骨细胞和成骨细胞的作用上。然而,现在很清楚,骨髓中的其他细胞类型,包括免疫系统细胞、间充质干细胞和骨髓基质细胞,也可以促成骨髓瘤性骨病的发展。这篇综述讨论了与骨髓瘤性骨病有关的细胞机制和潜在的治疗靶点。